Trial · NCT07902713
Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT07902713, Phase 2, Not yet recruiting, Sun Yat-sen University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma. Trials, record NCT07902713. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07902713
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma
- NCT number
- NCT07902713
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Sun Yat-sen University
- Conditions
- Nasopharyngeal Carcinoma (NPC)
- Interventions
- Becotatug Vedotin (MRG003), Gemcitabine (1000 mg/m2), Camrelizumab
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | From the first dose of study treatment until disease progression, initiation of new anticancer therapy, death, or the last tumor assessment, whichever occurs first (assessed up to approximately 24 months). | Objective response rate (ORR) is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR), as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, from the first dose of study treatment until disease progression, initiation of new anticancer therapy, death, or the last tumor assessment, whichever occurs first. |
| Secondary | Disease Control Rate (DCR) | From the first dose of study treatment until disease progression, initiation of new anticancer therapy, death, or the last tumor assessment, whichever occurs first (assessed up to approximately 24 months). | Disease control rate (DCR) is defined as the proportion of participants whose best overall response is complete response (CR), partial response (PR), or stable disease (SD), as assessed by the investigator according to RECIST version 1.1. |
| Secondary | Duration of Response (DoR) | From the first documented CR or PR until disease progression or death (assessed up to approximately 24 months). | Duration of response (DoR) is defined as the time from the first documented complete response (CR) or partial response (PR) to the first documented disease progression or death from any cause, whichever occurs first, among participants who achieve an objective response. |
| Secondary | Progression-Free Survival (PFS) | From the first dose of study treatment until disease progression or death (assessed up to approximately 24 months). | Progression-free survival (PFS) is defined as the time from the first dose of study treatment to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first. |
| Secondary | Overall Survival (OS) | From the first dose of study treatment until death from any cause (assessed up to approximately 24 months). | Overall survival (OS) is defined as the time from the first dose of study treatment to death from any cause. |
| Secondary | Incidence of Treatment-Related Adverse Events (TRAEs) | During study treatment and protocol-specified safety follow-up (approximately up to 24 months). | The proportion of participants experiencing at least one treatment-related adverse event (TRAE), with severity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. |
| Secondary | Incidence of Serious Adverse Events (SAEs) | During study treatment and protocol-specified safety follow-up (up to approximately 24 months). | The proportion of participants experiencing at least one serious adverse event (SAE), regardless of its relationship to study treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07902713
GET https://conductscience.org/api/trials/v1/NCT07902713/registered